 SALT LAKE CITY, May 25, 2021 PRNewswire -- Recursion Pharmaceuticals, Inc. Nasdaq : RXRX, a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning ML, and engineering, today announced the company has initiated investigational new drug IND-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile C. difficile infections and potential prophylactic use in high-risk patients. 